HORSHAM, Pennsylvania, May 28, 2026
Johnson & Johnson has secured a major regulatory milestone after the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) for TREMFYA® (guselkumab), expanding its label to include evidence demonstrating the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). The approval makes TREMFYA the only IL-23 inhibitor with FDA-recognized evidence showing the ability to help prevent further structural joint damage, reinforcing its position as a differentiated first-line treatment option for patients facing the debilitating consequences of progressive psoriatic arthritis. The expanded label is supported by compelling data from the Phase 3b APEX study, which demonstrated significant improvements in both disease symptoms and long-term joint preservation, addressing one of the most critical unmet needs in rheumatology.
FDA Label Expansion Reinforces TREMFYA’s Differentiated Clinical Profile
Psoriatic arthritis is a chronic inflammatory disease that affects joints, tendons, ligaments, and skin, causing pain, swelling, stiffness, fatigue, and progressive structural damage. Without effective intervention, irreversible joint damage can occur within months of disease onset, leading to permanent disability and reduced quality of life.
The FDA’s decision to expand the TREMFYA label represents a significant advancement for patients and healthcare providers by formally recognizing the therapy’s ability to inhibit structural damage progression. This outcome is particularly important because preserving joint integrity remains a primary treatment goal in psoriatic arthritis management.
TREMFYA is a fully human monoclonal antibody that selectively targets interleukin-23 (IL-23), a key inflammatory cytokine involved in immune-mediated diseases. The therapy also demonstrates a unique dual-acting mechanism through binding to CD64-positive immune cells, further differentiating it within the rapidly evolving immunology treatment landscape.
Advertisement
With the updated label, physicians now have stronger evidence supporting the use of TREMFYA not only for symptom control but also for long-term protection against irreversible joint destruction, helping patients maintain mobility, independence, and overall function.
Phase 3b APEX Study Demonstrates Significant Joint Protection
The label expansion is based on findings from the Phase 3b APEX trial, a randomized, double-blind, placebo-controlled study involving biologic-naïve patients with active psoriatic arthritis who had an inadequate response to standard therapies. The study successfully met both its primary endpoint of symptom improvement and its major secondary endpoint measuring inhibition of structural joint damage.
Researchers assessed structural damage using the PsA-modified van der Heijde-Sharp (vdH-S) score, a validated radiographic measure of disease progression. Results demonstrated that patients receiving TREMFYA experienced significantly less radiographic progression compared with placebo-treated participants.
Importantly, patients who initially received placebo and then switched to TREMFYA at Week 24 experienced a 57% reduction in radiographic progression between Weeks 24 and 48, indicating that the therapy can provide meaningful benefits even after disease progression has begun.
The study also confirmed TREMFYA’s well-established safety profile, with no new safety concerns identified. These findings further strengthen confidence in the therapy’s long-term use and support its role as a foundational treatment option for active psoriatic arthritis.
Expanding Johnson & Johnson’s Leadership in Immunology
The approval represents another important achievement for Johnson & Johnson’s growing immunology franchise. TREMFYA is already approved for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, ulcerative colitis, and Crohn’s disease, reflecting its broad therapeutic potential across immune-mediated disorders.
Industry experts view the label expansion as a meaningful competitive advantage within the biologics market, particularly as physicians increasingly prioritize therapies capable of preventing irreversible structural damage while maintaining favorable safety profiles. The ability to demonstrate both symptom improvement and disease modification positions TREMFYA as a highly differentiated treatment option in a crowded rheumatology landscape.
As healthcare systems continue emphasizing early intervention and long-term disease control, therapies that can preserve joint structure are becoming increasingly valuable. The FDA’s recognition of TREMFYA’s structural inhibition benefits provides additional clinical confidence for treatment decisions and may influence future treatment guidelines.
With this latest regulatory achievement, Johnson & Johnson further strengthens TREMFYA’s position as a leading biologic therapy in psoriatic arthritis, offering patients a powerful combination of symptom relief, durable disease control, and protection against irreversible joint damage that can significantly impact long-term health outcomes.
Source: Johnson & Johnson press release
